Vital Therapies Inc., of San Diego, which is developing Elad, a cell-based therapy targeting the treatment of acute forms of liver failure, said it priced an underwritten public offering of 8.75 million newly issued shares of its common stock at $4 per share for gross proceeds of approximately $35 million.